Amplistar files patents for cancer antibody markers:
This article was originally published in Clinica
Executive Summary
US biotech firm Amplistar has filed seven provisional patent applications in the US that focus on using specific antibodies for the early detection of colon, lung and prostate cancers. The Winston-Salem, North Carolina company claims that cancer antibodies can be detected in blood earlier than the tumour marker proteins that are identified by current cancer tests. Amplistar expects to file provisional patent applications covering 10 additional new antibody targets for several cancers by the end of the year.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.